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Abstract 
Background 
It has been reported that the histone deacetylase inhibitor (iHDAc) trichostatin A (TSA) 
induces an increase in MDR1 gene transcription (ABCB1). This result would compromise the 
use of iHDACs in combination with other cytotoxic agents that are substrates of P-
glycoprotein (Pgp). It has also been reported the use of alternative promoters by the ABCB1 
gene and the existence of a translational control of Pgp protein. Finally, the ABCB1 gene is 
located in a genetic locus with the nested gene RUNDC3B in the complementary DNA 
strand, raising the possibility that RUNDC3B expression could interfere with ABCB1 
alternative promoter regulation. 
Methods 
A combination of RT-PCR, real time RT-PCR, Western blot and drug accumulation assays 
by flow cytometry has been used in this study. 
Results 
The iHDACs-induced increase in MDR1 mRNA levels is not followed by a subsequent 
increase in Pgp protein levels or activity in several pancreatic and colon carcinoma cell lines, 
suggesting a translational control of Pgp in these cell lines. In addition, the MDR1 mRNA 
produced in these cell lines is shorter in its 5´ end that the Pgp mRNA produced in cell lines 
expressing Pgp protein. The different size of the Pgp mRNA is due to the use of alternative 
promoters. We also demonstrate that these promoters are differentially regulated by TSA. 
The translational blockade of Pgp mRNA in the pancreatic carcinoma cell lines could be 
related to alterations in the 5´ end of the MDR1 mRNA in the Pgp protein expressing cell 
lines. In addition, we demonstrate that the ABCB1 nested gene RUNDC3B expression 
although upregulated by TSA is independent of the ABCB1 alternative promoter used. 
Conclusions 
The results show that the increase in MDR1 mRNA expression after iHDACs treatment is 
clinically irrelevant since this mRNA does not render an active Pgp protein, at least in colon 
and pancreatic cancer cell lines. Furthermore, we demonstrate that TSA in fact, regulates 
differentially both ABCB1 promoters, downregulating the upstream promoter that is 
responsible for active P-glycoprotein expression. These results suggest that iHDACs such as 
TSA may in fact potentiate the effects of antitumour drugs that are substrates of Pgp. Finally, 
we also demonstrate that TSA upregulates RUNDC3B mRNA independently of the ABCB1 
promoter in use. 
Background 
Multidrug resistance (MDR) constitutes a major obstacle for success of cancer treatment. The 
MDR phenotype is responsible for resistance to a wide variety of anticancer drugs, such as 
anthracyclines, vinca-alkaloids and others [1]. Although several mechanisms could be 
involved in the acquisition of this phenotype, the role of two different membrane proteins, P-
glycoprotein (Pgp) and multidrug resistance associated protein (MRP), has been well 
established [2-4]. Both proteins are members of the same ATP-binding cassette (ABC) 
superfamily of transport proteins. Pgp was first identified as a consequence of its 
overexpression in multidrug-resistant tumour cells, where it mediates the ATP-dependent 
efflux of a variety of chemotherapeutic agents. In addition to its role during the acquisition of 
the MDR phenotype, Pgp is expressed in normal tissues, both as a consequence of 
differentiation and also in response to environmental challenges, and it has been proposed to 
play a role as a cell protector against cellular toxins [5]. In addition, a general antiapoptotic 
role for Pgp has been proposed [6]. It is clear that Pgp has several functions in different cells 
and tissues. 
Pgp is encoded by a multigene family in higher eukaryotes [7]. The ABCB1 gene (before 
MDR1) encodes the human Pgp. In cultured cells, constitutive overexpression of Pgp is 
mediated by changes in gene dosage or transcription. Pgp can also be transiently induced in 
cultured cells by a variety of stimuli, such as heat shock, UV radiation, and chemotherapeutic 
agents [8-11]. The regulation of Pgp expression has been mostly related to transcriptional 
control of the ABCB1 gene expression [8-11]. The proximal promoter of ABCB1 contains 
several regulatory regions, such as an inverted CCAAT box and a GC element, both of which 
are required for constitutive promoter activity in several cell lines [12-16]. It has been 
reported that in the colon carcinoma cell line SW620, the histone deacetylase inhibitor 
(iHDAC) trichostatin A (TSA), induces an increase in ABCB1 transcription through the 
inverted CCAAT box element, with the requirement of the NF-Y transcription factor [17]. 
This result can denote a big caveat, since a number of iHDACs are able to inhibit tumour 
growth, and several of them are used in clinical trials [18]. However, an increase in Pgp 
expression mediated by these inhibitors would hamper their combination with other cytotoxic 
agents that are substrates of Pgp. We have previously investigated in the human colon 
carcinoma cell lines SW620, HT-29 and HT-29/M6 the effect of TSA and Suberoylanilide 
Hydroxamic Acid (SAHA) on Pgp expression, demonstrating a translational control of Pgp 
expression [19]. The MDR1 mRNA produced in these cell lines is 285 bp shorter that the 
MDR1 mRNA produced in the human MCF-7/Adr and K562/Adr cell lines, both of them 
expressing Pgp protein. The different size of the MDR1 mRNA is due to the use of 
alternative promoters [19]. Interestingly, the ABCB1 gene is located in a genetic locus with 
the nested gene RUNDC3B in the complementary DNA strand. More specifically, several 
RUNDC3B exons are located in the complementary strand of the ABCB1 gene that 
corresponds with the intronic region between exon −1 and exon 1 of the MDR1 mRNA, 
raising the possibility of transcriptional interference between both genes. The study presented 
herein has been designed to gain insight in ABCB1 regulation determining whether the 
translational control of Pgp functions also in pancreatic cancer cell lines, the putative 
regulation of ABCB1 alternative promoters by iHDACs, and whether the expression of the 
ABCB1 nested gene RUNDC3B interferes with the expression of the MDR1 mRNA 
isoforms. 
Methods 
Cell lines and culture 
IMIM-PC-1, IMIM-PC-2, RWP-1, PANC-1, Hs-766 T and BxPC-3 pancreatic carcinoma cell 
lines, as well as HT-29, HT-29/M6, SW-620, HTC-15, DLD-1, Colo 320 HSR (Colo-320) 
and LS-174 T human colon carcinoma cell lines, were kindly donated by the IMIM cell line 
repository (IMIM, Barcelona, Spain). MCF-7/Adr (adriamycin resistant subline derived from 
MCF-7) human breast carcinoma cell line was kindly donated by the Vincent T. Lombardi 
Cancer Center (Georgetown University, Washington D.C). Cells were grown at 37 °C in 5 % 
CO2, with DMEM (Dulbecco’s Modified Eagle Medium) (Gibco BRL Invitrogen, Carlsbad, 
CA) or RPMI (DLD-1 and Colo-320 cells) supplemented with 10 % foetal calf serum 
(Biowhitaker, Velviers, Belgium), 2 mM L-glutamine (Gibco BRL Invitrogen, Carlsbad, 
CA), 1 mM sodium pyruvate when required (Gibco BRL Invitrogen, Carlsbad, CA), 50 U/ml 
penicillin and 50 μg/ml streptomycin (Gibco BRL Invitrogen, Carlsbad, CA). The murine 
leukaemia cell lines L1210, L1210R (daunomycin resistant subline derived from L1210), K-
562 (human erythroleukaemia cell line) and K562/Adr (adriamycin resistant subline derived 
from K-562) were grown as previously described [20]. 
Western blot 
Treated or untreated cells were washed twice with PBS. After scraping the cells with PBS, 
they were centrifuged at 1000 x g for 5 minutes. L1210R and K562Adr cells which grow in 
suspension were washed twice with PBS. Pgp expression was determined by Western 
immunoblot using the monoclonal antibody (mAb) C-219 (Centocor Inc), as previously 
described [21,22], followed by enhanced chemoluminiscence (ECL) (Amersham 
International, Buckinghamshire, UK) to develop protein bands. Protein concentration in the 
cell lysates was determined by the Bradford method (Bio-Rad, Richmond, CA). 
Drug accumulation studies 
Steady-state intracellular accumulation of the fluorescent substrate daunomycin (DNM) was 
determined as previously described, in the absence or in the presence of verapamil (VRP), an 
inhibitor of Pgp [23]. 
Real time RT- PCR 
To determine the level of MDR1 mRNA and RUNCD3B mRNA, total RNA from non treated 
or TSA-treated cells was isolated using the TRI reagent (Sigma-Aldrich, Co., St. Louis, MO). 
or the RNeasy Mini Kit (Qiagen GmbH, Germany). To eliminate potential DNA 
contamination, total RNA was treated with RQ1 DNase (Promega Corp. Madison, WI) for 30 
min at 37 °C followed by 2 min at 94 °C. Reverse transcription of 1 μg RNA was performed 
using the TaqMan Reverse Transcription Reagents kit (Applied Biosystems Foster City, CA), 
according to the manufacturers’s instructions. Real time quantitative PCR was performed to 
amplify 20 ng of cDNA using the ABI PRISM 7700 Sequence Detector System (Applied 
Biosystems, Foster City, CA). Primers and probe to amplify MDR1 mRNA and RUNCD3B 
mRNA are commercially available (Applied Biosystems, Foster City, CA). Glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) was used as endogenous reference in multiplex PCR. 
Primers and Taqman probe for this housekeeping gene are commercially available from 
Applied Biosystems (Taqman Pre-Developed Assay Reagents for gene expression). GAPDH 
Taqman probe was labeled with VIC in 5’ end as the reporter dye, and with TAMRA in 3’ 
end as the quencher dye. Relative expression of MDR1 and RUNCD3B mRNAs in tumour 
cell lines was determined by the comparative Ct method referred to the GAPDH 
housekeeping gene expression (ABI PRISM 7700 Sequence Detection System: User Bulletin 
#2, Applied Biosystems). 
RT-PCR analysis of the Pgp mRNA 
To study the long 5´UTR MDR1 mRNA, total RNA from the different cell lines was isolated, 
treated with RQ1 DNase and reverse transcribed as described above. The cDNAs obtained 
were amplified by PCR using the appropriate set of primers. The primers’s sequences were: 
F1 (CATTCCTCCTGGAAATTCAACCT) and R1 (CTTCAAGATCCATTCCGACCTC) for 
MDR1 mRNA coming from ABCB1 upstream promoter (USP) and F2: 
GTTTCGCTATTCAAATTGGC and R2 (iso): CAGCCTATCTCCTGTCGCATT for MDR1 
mRNA coming from both ABCB1 promoters (USP and DSP). The cDNAs were amplified by 
PCR as follows: 2 minutes at 94 °C, and then 40 cycles of: 30 seconds at 94 °C, 30 seconds at 
55 to 61 °C (depending on the set of primers), 45 seconds to 2 minutes (depending on the 
length of the amplified segment) at 72 °C, and 7 minutes at 72 °C. PCR products were 
resolved by electrophoresis on 0.5-2 % (w/v) agarose gels. Bands were visualized with 
ethidium bromide. 
Results 
Effect of histone deacetylase inhibitors on Pgp mRNA expression in different 
pancreatic carcinoma cell lines 
To determine iHDACs effects in MDR1 mRNA expression in human pancreatic carcinoma 
cell lines, we analyzed the level of MDR1 mRNA by real time RT-PCR in IMIM-PC-1, 
IMIM-PC-2 and RWP-1 human pancreatic carcinoma cell lines in the presence and absence 
of TSA and SAHA. Results in Figure 1A show that treatment with TSA or SAHA induced an 
increase in MDR1 mRNA levels in these cell lines. Despite this increase in MDR1 mRNA 
levels, we have previously reported that TSA and other iHDACs are able to inhibit cell 
growth and to induce apoptosis in these pancreatic carcinoma cell lines [24]. 
Figure 1 TSA effect on Pgp levels and activity in pancreatic cancer cells. A. MDR1 
mRNA levels determined by real time RT-PCR. IMIM-PC-1, IMIM-PC-2 and RWP1 cell 
lines were treated or not with 1 μM TSA or 7.5 μM SAHA for 24 h. GAPDH mRNA was 
also determined as internal control. Results are shown as the mean ± SD of at least three 
independent experiments with three replicates in each experiment. B. Western blot analysis of 
Pgp expression in IMIM-PC-1, IMIM-PC-2 and RWP1 pancreatic carcinoma cell lines 
treated or not with 1 μM TSA for 24 h. As a positive control the Pgp expressing K-562/Adr 
cell line was included. β-Actin is included as internal control. C. Pgp activity in the 
pancreatic carcinoma cell lines IMIM-PC-1, IMIM-PC-2 and RWP1 treated or nontreated 
with 1 μM TSA for 24 h and in the presence or absence of 2.5 μM verapamil (Pgp inhibitor). 
Pgp activity was estimated as daunomycin accumulation determined by flow cytometry. 
Daunomycin accumulation was also determined in the L1210R cell line for positive control 
Effect of histone deacetylase inhibitors on P-glycoprotein expression 
To test whether the increase observed in the level of MDR1 mRNA correlates with an 
increase in Pgp protein, we analyzed Pgp protein levels by Western immunoblot in IMIM-
PC-1, IMIM-PC-2 and RWP-1 cells in the presence or absence of TSA, using as a positive 
control the human erythroleukemia cell line K562Adr that expresses high levels of Pgp 
protein [20]. As shown in Figure 1B, there is no evidence of Pgp protein expression in these 
cell lines either before or after TSA treatment. To confirm that the lack of signal in the 
Western blot analysis of Pgp protein shown in Figure 1B was not due to the expression 
of a Pgp variant unable to react with the antibody used, Western blot analyses were 
performed with Pgp antibodies targeted againt different regions of the Pgp protein and 
we could not detect Pgp expression with any of the antibodies tested (data not shown). 
We also analyzed Pgp activity determining the accumulation of daunomycin (DNM), a 
fluorescent substrate of Pgp, in cells treated or untreated with iHDACs, using as a positive 
control L1210R cells. The presence of an active Pgp in these cell lines was demonstrated by 
the increased accumulation of DNM observed after addition of the Pgp inhibitor verapamil 
(VRP). Our results in Figure 1C show that no functional Pgp was present in IMIM-PC-1, 
IMIM-PC-2 and RWP-1 cell lines, either in the presence or in the absence of TSA. 
Translational control of Pgp mRNA in pancreatic carcinoma cell lines 
After demonstrating that the increase in MDR1 mRNA levels due to iDHACs treatment did 
not correspond with an increase in Pgp protein expression or activity, and since these results 
resembled our previous findings in colon carcinoma cell lines [19], we decided to determine 
whether the MDR1 mRNA present in pancreatic carcinoma cell lines included the longer or 
the shorter 5´ UTR form (Figure 2A), and whether the translational control was a general 
phenomenon in pancreatic cancer cells. In order to do that, we extended this study to other 
pancreatic cell lines. Results in Figure 2B show that neither the pancreatic carcinoma cell 
lines, IMIM-PC-1, IMIM-PC-2 and RWP-1 nor the new added cell lines Hs 766 T, BxPC-3 
and PANC-1 express the longer 5´UTR MDR1 mRNA, suggesting a generalized translational 
control of Pgp expression in human pancreatic carcinoma cell lines, since the new added cell 
lines were also negative for Pgp expression in Western blot analysis (data not shown). We 
have used K-562 ADR (erythroleukaemia cell line) and HTC-15 (colon carcinoma cell line) 
as positive controls, since both of them express a functional P-glycoprotein (19). 
Furthermore, Figure 3 shows the effects of TSA on MDR1 mRNA levels, as determined by 
real time RT-PCR in IMIM-PC-1, IMIM-PC-2, RWP-1, PANC-1, Hs 766 T and BxPC-3 
cells. All the cell lines except BxPC-3 show an increase in MDR1 mRNA levels after TSA 
treatment. 
Figure 2 Amplification by RT-PCR of the long 5´UTR MDR1 cDNA. A. Diagram 
showing two ABCB1 promoters and the MDR1 mRNA isoform produced by each promoter. 
B. RT-PCR amplification with F1 and R1 primers of the long 5´ UTR of the MDR1 cDNA. 
Lane 1. Molecular markers.Lanes 2–7. IMIM-PC-1, IMIM-PC-2, RWP-1, Hs 766 T, BxPC-3 
and PANC-1 cell lines. Lane 8.y 9, K-562/Adr and HTC-15 (positive controls) 
Figure 3 TSA effects on MDR1 mRNA in different pancreatic carcinoma cell lines. Hs-
766 T, BxPC-3, IMIM-PC-1, IMIM-PC-2, PANC-1 and RWP1cell lines were treated for 0–
24 hours with 1 μM TSA. As internal control GAPDH mRNA was also determined. Results 
are shown as the mean ± SD of at least three independent experiments with three replicates in 
each experiment 
TSA regulates differentially the ABCB1 promoters 
The longer and the shorter 5´ UTR forms of MDR1 mRNA have been related to the existence 
of two ABCB1 alternative promoters [19,25]. To determine the effects of TSA on both 
ABCB1 gene promoters, we analyzed the levels of MDR1 mRNA after 24 h treatment with 
TSA in a panel of cell lines of different origin that have been divided in two groups. Group A 
includes cell lines that we have analyzed previously and use the downstream promoter (DSP) 
which transcribes the short 5´UTR MDR1mRNA (the pancreatic carcinoma cell lines 
described above, the colon carcinoma cell lines HT-29, HT-29/M6 and SW620, the MCF-7 
breast carcinoma cell line and the K-562 erythroleukaemia cell line). Group B includes cell 
lines which use the upstream promoter (USP) that transcribes the long 5´UTR MDR1 mRNA 
(the HTC-15 colon carcinoma cell line, the MCF-7/Adr breast carcinoma cell line and the K-
562Adr erythroleukaemia cell line). Results in Figure 4 clearly demonstrate differential 
effects of TSA on DSP and USP promoters and suggest that TSA is able to downregulate the 
USP promoter and upregulate the DSP promoter in the ABCB1 gene. To further demonstrate 
that TSA downregulates the USP promoter and therefore inhibits the expression of an active 
P-glycoprotein, we decided to include in this study three additional colon carcinoma cell 
lines: LS-174 T, Colo-320 and DLD-1 that express P-glycoprotein, as shown by Western blot 
analysis in Figure 5A. Figure 5B shows that these cell lines express the long 5´-UTR MDR1 
mRNA and, furthermore, that TSA treatment decreased the levels of expression of the long 
5´-UTR MDR1 mRNA in all of them. Even more, we used K-562 cell sublines resistant to 
different concentrations of daunomycin that have been generated in our laboratory by 
selective pressure with increasing concentrations of the drug. We have previously shown that 
resistance to daunomycin in this sublines was related to the active expression of P-
glycoprotein, and that this expression correlates with the expression of the long 5´-UTR 
MDR1 mRNA [19]. As shown in Figure 5C, TSA was able to increase daunomycin 
accumulation in the K-562 d20 (resistant to 20 nM daunomycin), a subline that expresses P-
glycoprotein and the long 5´-UTR MDR1 mRNA associated with the UPS promoter [19]. 
This result suggests that TSA decreases P-glycoprotein expression leading to an increased 
accumulation of daunomycin in these cells. Futhermore, as shown in Figure 5C, TSA 
downregulated MDR1 mRNA, as determined by real time PCR in K-562 d450, a cell subline 
which expresses high levels of P-glycoprotein and also the long 5´-UTR MDR1 mRNA (19). 
Meanwhile, TSA increased the expression of the MDR1 mRNA in the parental K562 that 
does not express P-glycoprotein and expresses the short 5´-UTR MDR1 mRNA. 
Figure 4 Differential effect of TSA on ABCB1 alternative promoters. Group A cell lines 
(Hs-766 T, IMIM-PC-1, IMIM-PC-2, RWP1, PANC-1, MCF-7, K-562, HT-29, HT-29/M6, 
SW620 and BxPC-3) expressing the short 5´UTR MDR1 mRNA and group B cell lines 
(HTC-15, K5-62/Adr and MCF-7/Adr) expressing the long 5´UTR MDR1 mRNAs were 
treated for 24 hours with 1 μM TSA. As internal control GAPDH mRNA was also 
determined. Results are shown as the mean ± SD of at least three independent experiments 
with three replicates in each experiment 
Figure 5 TSA dual regulation of ABCB1 promoters. A. Western blot analysis of Pgp 
expression in K-562 (lane 1), K-562/Adr (lane 2), negative and positive control respectively 
and the colon carcinoma cell lines Colo 320 (lane 3), DLD-1 (lane 4) and LS 174 T (lane 5). 
β-Actin is included as internal control. B. RT-PCR amplification with F1 and R1 primers of 
the long 5´ UTR of the MDR1 cDNA. Lane 1. Molecular markers. Lanes 2 and 3.K562/Adr 
and HTC-15 (positive controls). Lane 4, 6 and 8, Ls174T, Colo320 and DLD1 untreated cell 
lines. Lane 5, 7 and 9, Ls174T, Colo320 and DLD1 cell lines treated with 1 μM TSA for 24 
h. C. Pgp activity in the erythroleukaemia cell lines K-562 (negative control), K-562 (d20) 
and K-562/Adr (positive control) treated or no treated with 1 μM TSA for 24 h and in the 
presence or absence of 2.5 μM verapamil (Pgp inhibitor). Pgp activity was estimated as 
daunomycin accumulation determined by flow cytometry. C. MDR1 mRNA levels 
determined by real time RT-PCR. K-562, K-562 (d450) and K-562/Adr cell lines were 
treated or not with 1 μM TSA for 24 h. GAPDH mRNA was also determined as internal 
control. Results are shown as the mean ± SD of at least three independent experiments with 
three replicates in each experiment 
TSA effect on RUNDC3B mRNA levels 
The ABCB1 gene is located in a genetic locus with the nested gene RUNDC3B in the 
complementary DNA strand (see Figure 6A). Based on this special localization, we 
investigated whether the expression of RUNDC3B mRNA was regulated by TSA and 
whether the expression of this mRNA was related to the expression of the short or the long 
5´UTR of the MDR1 mRNA. As shown in Figure 6B, TSA upregulates RUNDC3B mRNA 
expression levels independently of the MDR1 mRNA isoform (DSP or USP) expressed in the 
different cell lines. 
Figure 6 Effect of TSA on RUNDC3B mRNA expression. A. Diagram showing the 
overlapping of ABCB1 intron and RUNDC3B exons. B. Hs-766 T, BxPC-3, IMIM-PC-1, 
IMIM-PC-2, PANC-1, RWP1, HTC-15,MCF-7/Adr, LS 174 T, DLD-1 and Colo 320 cell 
lines were non treated or treated for 24 hours with 1 μM TSA and RUNDC3B mRNA 
expression were determined. As internal control GAPDH mRNA levels were also 
determined. Results are shown as the mean ± SD of at least three independent experiments 
with three replicates in each experiment 
Discussion 
In the present study, we demonstrate that the increase in MDR-1 mRNA levels induced by 
iHDACs inhibitors in pancreatic adenocarcinoma cell lines does not parallel an increase in 
Pgp protein or in Pgp activity. This observation is important since we and others have 
reported that the histone deacetylase inhibitors TSA and SAHA induce two major effects in 
several drug-resistant cells lines: down-regulation of Pgp and induction of apoptosis. In that 
sense, we have demonstrated that TSA markedly reduced Pgp expression in the L1210R 
drug-resistant murine cell line [20] and “sensitized” these cells to daunomycin [26,27], as 
shown in Figure 1C, where TSA treatment increases DNM accumulation in L1210R cells, 
suggesting that iHDACs might have a therapeutic potential against chemoresistant tumours. 
However, other authors had reported an increase in the steady-state level of MDR1 mRNA 
upon treatment with TSA [17], suggesting that iHDACs could not be utilized in combination 
with other cytotoxic agents that are substrates of Pgp. Our results in pancreatic carcinoma cell 
lines, which are in agreement with our previously published results in colon carcinoma cell 
lines [19], strongly suggest that expression of MDR1 mRNA is necessary but not sufficient 
for Pgp protein expression. 
Next, we tried to identify the putative mechanisms involved in this phenomenon and we 
concluded that a translational blockade of Pgp expression takes place in pancreatic carcinoma 
cell lines, in agreement with our previous studies in colon carcinoma cell lines after TSA 
treatment [19] and in the human erytroleukaemia K-562 cell line [28]. 
Our data suggest that the translational blockade of MDR1 mRNA in the colon and pancreatic 
carcinoma cell lines and in K-562 cells could be overcome by alterations in the 5´ end of the 
MDR1 mRNA in the resistant variants of these cell lines. These results are especially relevant 
since we have previously demonstrated the relationship between the expression of the long 
5´UTR MDR1 mRNA and the final expression of an active Pgp protein [19]. The origin and 
nature of these MDR1 mRNA isoforms became clear when Raguz et al. [22] reported the 
presence of an ABCB1 gene upstream promoter in breast carcinoma samples. Both promoters 
would translate the same protein because they use the same ATG codon, but the mRNA 
transcribed from the upstream promoter is approximately 285 bp longer in its 5´ end than the 
MDR1 mRNA transcribed from the downstream promoter. Our data, together with results 
published by other groups, strongly suggest that expression of MDR1 mRNA is necessary but 
not sufficient for Pgp protein expression, indicating that MDR1 mRNA is subjected to a 
negative translational control. During the acquisition of chemoresistance there is a switch 
from the downstream to the upstream ABCB1 gene promoter, and this promoter transcribes a 
MDR1 mRNA that is translated more efficiently. To sustain this hypothesis, we have 
demonstrated that the expression of an active Pgp protein correlates with the activation of the 
upstream promoter of the ABCB1 gene in several K-562 cellular sublines obtained by 
selective pressure with increasing concentrations of daunomycin [19] and Figure 5. 
In addition, the results shown herein demonstrate that short and long 5´UTR MDR1 mRNAs 
are differentially regulated by the histone deacetylase inhibitor TSA, indicating that both 
promoters are differentially regulated by iHDACs. This is a compelling observation because 
TSA is able not only to downregulate the promoter responsible for active Pgp protein 
expression but also to induce apoptosis in colon and pancreatic carcinoma cells, sensitizing 
them to other chemotherapeutic agents that are substrates of Pgp. In addition, we observed 
that TSA increased MDR1 mRNA in the parental K-562 cells, whereas TSA decreased 
MDR1 mRNA levels in the daunomycin-resistant K-562 sublines which express Pgp protein 
and employ the USP promoter. This suggests again a differential regulation by TSA of both 
ABCB1 promoters. 
We have also study the effect of TSA on the regulation of the RUNDC3B gene, since this is a 
nested gene transcribed from the ABCB1complementary DNA strand. These studies were 
designed to test the hypothesis that the regulation of the ABCB1 nested gene RUNDC3B 
could interfere with the alternative expression of both 5´UTR MDR1 mRNAs, since some of 
the exons of the RUNDC3B mRNA lie on the complementary strand of the ABCB1 gene, as 
shown in Figure 6A. Our results demonstrate that TSA is able to increase RUNDC3B mRNA 
levels, independently of the ABCB1 promoters that are active in these cell lines. RUNDC3B 
has been related to a more metastatic phenotype in breast cancer patients [29]. According to 
this, we could speculate a selection of RUNDC3B expression in colon and pancreatic 
carcinoma cell lines, instead of a functional Pgp protein expression, since expression of 
RUNDC3B could represent an additional advantage in their evolution to a more aggressive 
phenotype. However, taking into consideration our results, we cannot conclude that the 
expression of RUNDC3B could be in some way incompatible with the ABCB1 USP 
promoter expression forcing the cells to use the DSP promoter. 
Although our data fit quite well with the existence of two ABCB1 promoters, some authors 
[30] have found that the additional 5´-UTR that is important for P-glycoprotein expression is 
due not to the use of an alternative promoter, but mostly to epigenetic changes in the region 
where this additional exon lies (112 kb upstream of the short MDR1 mRNA transcription 
initiation site). In fact, and based on chromatin immunoprecipitation assays and transient 
transfection of reporter genes under the control of the putative region where UPS promoter 
lies, they concluded that the reason for the alternative 5´-UTR MDR1mRNA expression is 
due to epigenetic changes, mostly related to histone H3 acetylation. The situation in the 
putative upstream promoter cannot be explained only by histone acetylation because 
TSA generally produces a state of hyperacetylation due to histone deacetylases 
inhibition. Global general hyperacetylation is related to an increase in transcription and 
however upstream promoter transcription is inhibited. Epigenetic control of Pgp 
expression has been previously suggested by different authors, which found that 
demethylating agents were able to induce Pgp- mediated chemoresistance in different cellular 
models [31-33], We have some preliminary data with primary cultures derived from 
tumours of patients with colon cancer. In some of these cultures, we found that Pgp 
expression was lost. In some clonal populations obtained by extreme dilution of these 
cultures the long MDR1mRNA isoform and Pgp expression after treatment with DNA 
demethylating agents was recovered, suggesting that DNA methylation is involved in the 
expression of the MDR1mRNA isoforms (data not shown). However, it is unclear whether 
Pgp expression is regulated by two different promoters or by epigenetic mechanisms that 
modifies the activity of a single promoter. Since TSA is an epigenetic drug, from our results 
it is difficult to discriminate whether TSA downregulates the UPS promoter or, alternatively 
modifies the epigenetic status of a specific region of the ABCB1 gene. In any case, we can 
affirm that TSA inhibits the expression of an active P-glycoprotein. The authors that 
argument the epigenetic changes as the main reason for the long 5´-UTR MDR1mRNA 
production suggest that the nested gene RUNDC3B is only expressed when the long 5´-UTR 
MDR1mRNA is expressed, or in other words that there is a correlation between the 
expression of both mRNAs. Our data do not support this hypothesis, because as seen in 
Figure 6B, RUNDC3B mRNA is expressed in cell lines that express the short 5´-UTR MDR1 
mRNA, suggesting that the expression of both genes is not regulated simultaneously by the 
same epigenetic changes in a specific genomic region. 
Conclusions 
The results shown herein show that the risk of a putative increase in Pgp expression after 
iHDACs treatment is clinically irrelevant since it does not render an active Pgp protein, at 
least in colon and pancreatic cancer cell lines. In addition, we have demonstrated that TSA 
regulates differentially both ABCB1 promoters and upregulates RUNDC3B mRNA 
expression levels independently of the ABCB1 promoter in use. 
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